In the last trading session, 1.16 million shares of the Macrogenics Inc (NASDAQ:MGNX) were traded, and its beta was 2.09. Most recently the company’s share price was $2.40, and it changed around -$0.14 or -5.51% from the last close, which brings the market valuation of the company to $150.63M. MGNX currently trades at a discount to its 52-week high of $21.88, offering almost -811.67% off that amount. The share price’s 52-week low was $2.53, which indicates that the current value has fallen by an impressive -5.42% since then. We note from Macrogenics Inc’s average daily trading volume that its 10-day average is 0.85 million shares, with the 3-month average coming to 571.92K.
Macrogenics Inc stock received a consensus recommendation rating of Hold, based on a mean score of 2.18. If we narrow it down even further, the data shows that 0 out of 11 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 7 recommended MGNX as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight. Macrogenics Inc is expected to report earnings per share of -0.66 for the current quarter.
Macrogenics Inc (NASDAQ:MGNX) trade information
Instantly MGNX has showed a red trend with a performance of -5.51% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 3.02 on recent trading dayincreased the stock’s daily price by 20.53%. The company’s shares are currently down -26.15% year-to-date, but still down -15.79% over the last five days. On the other hand, Macrogenics Inc (NASDAQ:MGNX) is -24.53% down in the 30-day period. We can see from the shorts that 5.44 million shares have been sold at a short interest cover period of 8.93 day(s).
The consensus price target as assigned by Wall Street analysts is $8, which translates to bulls needing to increase their stock price by 70.0% from its current value. Analyst projections state that MGNX is forecast to be at a low of $4 and a high of $32.
Macrogenics Inc (MGNX) estimates and forecasts
The year-over-year growth rate is expected to be 168.88%, up from the previous year.
Consensus estimates provided by 7 financial analysts predict the company will bring in an average of 30.93M in revenue for the current quarter. 4 analysts expect Macrogenics Inc to make 9.32M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 10.72M and 9.1M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 188.53%. Forecasts for the next quarter put sales growth at 2.43%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 48.88%.
MGNX Dividends
Macrogenics Inc’s next quarterly earnings report is expected to be released in March.
Macrogenics Inc (NASDAQ:MGNX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 2.65% of Macrogenics Inc shares, and 93.33% of them are in the hands of institutional investors. The stock currently has a share float of 95.87%. Macrogenics Inc stock is held by 176.0 institutions, with BELLEVUE GROUP AG being the largest institutional investor. By 2024-06-30, it held 15.9612% of the shares, which is about 9.94 million shares worth $42.25 million.
ARMISTICE CAPITAL, LLC, with 9.6323% or 6.0 million shares worth $25.5 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF were the top two Mutual Funds as of Sep 30, 2024. The former held 2.0 shares worth $4.8 million, making up 3.19% of all outstanding shares. On the other hand, iShares Russell 2000 ETF held roughly 1.72 shares worth around $4.14 million, which represents about 2.75% of the total shares outstanding.